Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.09.2013 | main topic

Renale Osteodystrophie

verfasst von: Daniel Cejka, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 17-18/2013

Einloggen, um Zugang zu erhalten

Summary

The incidence of renal osteodystrophy (ROD) increases with deteriorating kidney function, affecting virtually every patient on chronic dialysis treatment. ROD can persist after kidney transplantation and may be aggravated by immunosuppressants, mainly glucocorticoids. Fracture risk, including hip fractures, is markedly elevated in patients with renal disease compared to the general population. Depending on the type of ROD, high or low bone turnover can be found. Because of poor positive and negative predictive values of serological markers of bone turnover and limited technical capabilities of various bone imaging modalities, the only reliable method to correctly classify ROD is the transiliac bone biopsy. Elevated bone turnover can be successfully treated with active vitamin D, cinacalcet, or parathyreoidectomy, but all of these therapies may lead to oversuppression of bone metabolism. Currently, no specific therapy is available for low turnover bone disease. Bisphosphonates can be a therapeutic option for selected patients after renal transplantation.
Vorheriger Artikel Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy
Nächster Artikel Internationaler Status Dickdarmkrebs-Screening und Qualitätssicherung der Screening-Koloskopie
Literatur
1.
Moe S, Drüeke T, Block G, Cannata-Andia J, Elder G, Fukagawa M, et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009 Aug 1;76(S 113):S1–130.
2.
Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011 Apr;6(4):913–21.PubMedCrossRef
3.
Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725–30.PubMedCrossRef
4.
Lehmann G, Ott U, Stein G, Steiner T, Wolf G. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc. 2007 Dec;39(10):3153–8.PubMedCrossRef
5.
Kodras K, Haas M. Effect of kidney transplantation on bone. Eur J Clin Invest. 2006 Aug;36 (Suppl 2):63–75.PubMedCrossRef
6.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006 Apr 26;69(11):1945–53.PubMedCrossRef
7.
Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995 Oct;26(4):622–31.PubMedCrossRef
8.
Herberth J, Monier-Faugere MC, Mawad HW, Branscum AJ, Herberth Z, Wang G, et al. The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. Clin Nephrol. 2009 Jul;72(1):5–14.PubMedCrossRef
9.
Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, et al. Downregulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000 Oct;58(4):1440–9.PubMedCrossRef
10.
Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000 Aug;58(2):753–61.PubMed
11.
Duursma SA, Visser WJ, Mees EJ, Njio L. Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency. Calcif Tissue Res. 1974;16(2):129–38.PubMedCrossRef
12.
Couttenye MM, D’Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant. 1996 Jun 1;11(6):1065–72.PubMedCrossRef
13.
Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int. 1984 Dec;26(6):869–74.PubMedCrossRef
14.
Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Manni M, et al. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol. 1992;12(4):246–51.PubMedCrossRef
15.
Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis. 2002 Oct;40(4):802–9.PubMedCrossRef
16.
Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, et al. Osteoprotegerin and parathyroid hormone as markers of high turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis. 2002 Mar;39(3):580–6.PubMedCrossRef
17.
Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011 Apr;6(4):877–82.PubMedCrossRef
18.
Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol. 2000 Nov;13(6):437–43.PubMed
19.
Lindergard B, Johnell O, Nilsson BE, Wiklund PE. Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment. Nephron. 1985;39(2):122–9.PubMedCrossRef
20.
Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a metaanalysis. Am J Kidney Dis. 2007 May;49(5):674–81.PubMedCrossRef
21.
Smith JA, Vento JA, Spencer RP, Tendler BE. Aortic calcification contributing to bone densitometry measurement. J Clin Densitom. 1999;2(2):181–3.PubMedCrossRef
22.
Jamal SA, Gilbert J, Gordon C, Bauer DC. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res. 2006 Apr;21(4):543–8.PubMedCrossRef
23.
Amling M, Herden S, Posl M, Hahn M, Ritzel H, Delling G. Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res. 1996 Jan;11(1):36–45.PubMedCrossRef
24.
Cejka D, Patsch JM, Weber M, Diarra D, Riegersperger M, Kikic Z, et al. Bone microarchitecture in hemodialysis patients assessed by HR-pQCT. Clin J Am Soc Nephrol. 2011 Sep;6(9):2264–71. (Epub 2011 Jul 7)PubMedCrossRef
25.
Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in bone mass early after kidney transplantation. J Bone Miner Res. 1994 Jan;9(1):1–9.PubMedCrossRef
26.
Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis. 1996 Jul;28(1):105–14.PubMedCrossRef
27.
Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, et al. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis. 2000 Feb;35(2):227–36.PubMedCrossRef
28.
Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant. 1995 Nov;10(11):2096–100.PubMed
29.
Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991 Aug 22;325(8):544–50.PubMedCrossRef
30.
Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, et al. Bone loss in long-term renal transplantation: histopathology and densitometry analysis. Kidney Int. 1999 May;55(5):2021–9.PubMedCrossRef
31.
Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994 Oct 27;58(8):912–5.PubMedCrossRef
32.
Akaberi S, Simonsen O, Lindergard B, Nyberg G. Can DXA predict fractures in renal transplant patients? Am J Transplant. 2008 Dec;8(12):2647–51.PubMedCrossRef
33.
Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000 Jul;58(1):396–9.PubMedCrossRef
34.
Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006 Oct;70(7):1358–66.PubMedCrossRef
35.
National Institutes of Health NIoDaDaKDBM. U.S. Renal data system, USRDS 2010
36.
Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004 Oct;44(4):672–9.PubMed
37.
Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002 Dec 18;288(23):3014–8.PubMedCrossRef
38.
Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001 Oct;11(7):450–7.PubMedCrossRef
39.
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all cause and cardiovascular mortality. Nephrol Dial Transplant. 2003 Sep;18(9):1731–40.PubMedCrossRef
40.
Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, et al. Presence of abdominal aortic calcification is significantly associated with all cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007 Mar;49(3):417–25.PubMedCrossRef
41.
Pirklbauer M, Mayer G. The exchangeable calcium pool: physiology and pathophysiology in chronic kidney disease. Nephrol Dial Transplant. 2011 Aug;26(8):2438–44.PubMedCrossRef
42.
London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004 Jul;15(7):1943–51.PubMedCrossRef
43.
London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008 Sep;19(9):1827–35.PubMedCrossRef
44.
Asci G, Ok E, Savas R, Ozkahya M, Duman S, Toz H, et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant. 2011 Mar;26(3):1010–5. (Epub 2010 Aug 13)PubMedCrossRef
45.
Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001 Jul;12(7):1530–7.PubMed
46.
Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003 Mar;63(3):1130–6.PubMedCrossRef
47.
Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003 Oct;14(10):2669–76.PubMedCrossRef
48.
Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005015.
49.
Andress DL, Maloney NA, Endres DB, Sherrard DJ. Aluminum associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res. 1986 Oct;1(5):391–8.PubMedCrossRef
50.
Andress DL, Nebeker HG, Ott SM, Endres DB, Alfrey AC, Slatopolsky EA, et al. Bone histologic response to deferoxamine in aluminum related bone disease. Kidney Int. 1987 Jun;31(6):1344–50.PubMedCrossRef
51.
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009 Aug;(113):S1–130. 130. doi: 10.1038/ki.2009.188.
52.
Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008 Feb;19(2):405–12.PubMedCrossRef
53.
D’Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003 Jun;(85):S73–8.
54.
Baker LR, Abrams SM, Roe CJ, Faugere MC, Fanti P, Subayti Y, et al. Early therapy of renal bone disease with calcitriol: a prospective double blind study. Kidney Int Suppl. 1989 Nov;27:S140–2.
55.
Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988 Nov;67(5):929–36.PubMedCrossRef
56.
Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol. 1986 Oct;26(4):185–91.PubMed
57.
Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989 Aug 3;321(5):274–9.PubMedCrossRef
58.
Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995 Feb 11;310(6976):358–63.PubMedCrossRef
59.
Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor 23 in secondary hyperparathyroidism. Kidney Int. 2011 Jan;79(1):112–9.PubMedCrossRef
60.
Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998 Aug;9(8):1427–32.PubMed
61.
Hayashi M, Tsuchiya Y, Itaya Y, Takenaka T, Kobayashi K, Yoshizawa M, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant. 2004 Aug;19(8):2067–73.PubMedCrossRef
62.
de Sevaux RGL, Hoitsma AJ, Corstens FHM, Wetzels JFM. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol. 2002 Jun 1;13(6):1608–14.PubMedCrossRef
63.
El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol. 2003 Nov 1;14(11):2975–9.PubMedCrossRef
64.
Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc. 2002 Sep;34(6):2111–3.PubMedCrossRef
65.
Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, et al. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc. 2000 Nov;32(7):1876.PubMedCrossRef
66.
El-Husseini AA, El-Agroudy AE, El-Sayed M, Sobh MA, Ghoneim MA. A prospective randomized study for the treatment of bone loss with vitamin d during kidney transplantation in children and adolescents. Am J Transplant. 2004 Dec;4(12):2052–7.PubMedCrossRef
67.
Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal transplant patients receiving low doses of steroids. Transplantation. 2005 Jan 15;79(1):108–15.PubMedCrossRef
68.
Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994 Oct;46(4):1160–6.PubMedCrossRef
69.
Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008 Apr;69(4):269–78.PubMedCrossRef
70.
Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793–800.PubMedCrossRef
71.
Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94. (Epub 2012 Nov 6)PubMedCrossRef
72.
Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis associated adynamic bone disease with teriparatide (PTH(1–34)): a pilot study. Kidney Blood Press Res. 2010 Jun 24;33(3):221–6.PubMedCrossRef
Metadaten
Titel
Renale Osteodystrophie
verfasst von
Daniel Cejka, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 17-18/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0195-3

Weitere Artikel der Ausgabe 17-18/2013

Bone turnover in hyperparathyroidism

  • main topic

Congenital complete and partial absence of the left pericardium

  • short communication

Internationaler Status Dickdarmkrebs-Screening und Qualitätssicherung der Screening-Koloskopie

  • originalarbeit

Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy

  • main topic

Hyperparathyroidism

  • editorial

Die Elektropathologie in Wien – eine Sammlung zur Unfallverhütung

  • bericht